US-based spinal implant solutions provider Aurora Spine has entered a worldwide distribution and co-marketing deal with Sentio to distribute the mechanomyography (MMG) nerve mapping system.

The Sentio MMG is a surgical access tool, offering improved technology for surgeons when compared with traditional techniques.

Sentio MMG locates and maps motor nerve roots and their peripheral extensions originating from spinal levels C3-T1 and L2-S2.

Aurora Spine CEO Trent Northcutt said: "This co-marketing strategy strengthens our position at the forefront of minimally invasive spine surgery technologies.

"Sentio MMG locates and maps motor nerve roots and their peripheral extensions originating from spinal levels C3-T1 and L2-S2."

"We are excited about our relationship with Sentio MMG in conjunction with our VOX MIS lateral interbody system featuring TiNANO.

"The Sentio system was specifically designed to facilitate safe MMG monitoring during any minimally invasive spine surgery (MIS)."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Smart sensors in the system employ a proprietary technology, using non-invasive accelerometer-based sensors to measure MMG activity, or the mechanical twitch associated with muscle contraction.

Sentio market development vice-president Sean Parker said: "Aurora’s MIS, tech-company culture fits extremely well with Sentio.

"We share a common ethos that will help drive both organizations to success as we co-market our technologies."

The system is cleared by US Food and Drug Administration (FDA) to assist in locating and mapping motor nerves through the use of mechanomyographic signals and electrical stimulus of nerves.

The Sentio MMG system also has a CE Mark for use in the European Union (EU) and other markets.